Wellington Management Group LLP Has $90.83 Million Stock Position in Insulet Corporation $PODD

Key Points

• Wellington Management Group LLP reduced its holdings in Insulet Corporation by 98.4% in the first quarter, now owning just 345,868 shares, worth approximately $90.8 million.
• Insulet has shown strong financial performance, reporting $1.17 earnings per share for the last quarter, exceeding analyst expectations, with revenue growth of 32.9% year-over-year.
• Multiple analysts have maintained a buy rating on Insulet stock, with target prices ranging from $331 to $380, reflecting confidence in the company's growth potential.

Wellington Management Group LLP reduced its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 98.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 345,868 shares of the medical instruments supplier's stock after selling 20,924,465 shares during the quarter. Wellington Management Group LLP owned approximately 0.49% of Insulet worth $90,828,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Insulet by 55.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after acquiring an additional 1,867 shares during the period. Farther Finance Advisors LLC lifted its holdings in Insulet by 85.1% during the 1st quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock worth $236,000 after purchasing an additional 412 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in Insulet by 75.6% during the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock worth $533,000 after purchasing an additional 874 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in Insulet by 225.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock worth $408,000 after purchasing an additional 1,075 shares during the last quarter. Finally, State of Alaska Department of Revenue lifted its holdings in Insulet by 2.6% during the 1st quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier's stock worth $2,156,000 after purchasing an additional 210 shares during the last quarter.

Insulet Price Performance

PODD traded up $2.73 on Wednesday, hitting $334.56. 111,364 shares of the stock were exchanged, compared to its average volume of 758,162. Insulet Corporation has a 12 month low of $191.77 and a 12 month high of $334.89. The business has a 50-day moving average of $301.94 and a two-hundred day moving average of $286.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The firm has a market capitalization of $23.55 billion, a price-to-earnings ratio of 101.68, a PEG ratio of 2.76 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same quarter in the previous year, the firm earned $0.55 EPS. Insulet's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PODD shares. Oppenheimer lifted their price target on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Citigroup reissued a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Truist Financial started coverage on Insulet in a report on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Morgan Stanley reissued an "overweight" rating on shares of Insulet in a report on Thursday, August 7th. Finally, Wells Fargo & Company lifted their price objective on Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.